These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 26909925

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas.
    Reddy KS.
    Cancer Genet Cytogenet; 2008 Jul 15; 184(2):77-86. PubMed ID: 18617055
    [Abstract] [Full Text] [Related]

  • 8. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL.
    Clin Neurol Neurosurg; 2019 Jul 15; 182():32-36. PubMed ID: 31063969
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F, Pontoizeau C, Tchara L, Di Stefano AL, Kamoun A, Deelchand DK, Valabrègue R, Lehéricy S, Sanson M, Ottolenghi C, Marjańska M.
    Neuro Oncol; 2019 Jun 10; 21(6):765-774. PubMed ID: 30726924
    [Abstract] [Full Text] [Related]

  • 11. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ.
    Carcinogenesis; 2019 Oct 16; 40(10):1229-1239. PubMed ID: 31157866
    [Abstract] [Full Text] [Related]

  • 12. MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.
    Patel SH, Batchala PP, Mrachek EKS, Lopes MS, Schiff D, Fadul CE, Patrie JT, Jain R, Druzgal TJ, Williams ES.
    Radiology; 2020 Jan 16; 294(1):160-167. PubMed ID: 31714193
    [No Abstract] [Full Text] [Related]

  • 13. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.
    Chin Med J (Engl); 2010 Dec 16; 123(24):3566-73. PubMed ID: 22166632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z, Lan Y, Wang L, Ge J, Wang J, Liu F, He Z, Zhang H, Luo M, Lin D, Tan Y, Xu Y, Luo T.
    BMC Cancer; 2020 Nov 09; 20(1):1072. PubMed ID: 33167941
    [Abstract] [Full Text] [Related]

  • 16. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
    Zhang Y, Xie Y, He L, Tang J, He Q, Cao Q, Cui L, Guo W, Hua K, Dimberg A, Wang L, Zhang L.
    Cell Oncol (Dordr); 2021 Feb 09; 44(1):193-204. PubMed ID: 32915415
    [Abstract] [Full Text] [Related]

  • 17. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
    Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R.
    Clin Cancer Res; 2017 Oct 15; 23(20):6078-6085. PubMed ID: 28751449
    [Abstract] [Full Text] [Related]

  • 18. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.
    Zhonghua Zhong Liu Za Zhi; 2011 Oct 15; 33(10):752-8. PubMed ID: 22335907
    [Abstract] [Full Text] [Related]

  • 19. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC, Lo CM, Wang SH, Su EC.
    BMC Bioinformatics; 2019 Dec 24; 20(Suppl 19):659. PubMed ID: 31870275
    [Abstract] [Full Text] [Related]

  • 20. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.
    Stockhammer F, Thomale UW, Plotkin M, Hartmann C, Von Deimling A.
    J Neurosurg; 2007 Apr 24; 106(4):633-7. PubMed ID: 17432715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.